Trial Profile
The Use of Picato (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms PrAKtice
- Sponsors LEO Pharma
- 11 Jan 2018 Status changed from active, no longer recruiting to completed.
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.